Old cancer drug shows new promise for rare, painful skin diseases
NCT ID NCT06545695
First seen Feb 03, 2026 · Last updated Apr 30, 2026 · Updated 9 times
Summary
This study tests a low-dose cancer drug called erlotinib in 44 adults with rare genetic skin disorders that cause severe thickening, scaling, and pain. The goal is to see if the drug can reduce skin symptoms and improve mobility. Participants will take the drug daily for 24 weeks, and researchers will monitor side effects and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALMOPLANTAR KERATODERMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Dermatology, Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.